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Background
An outstanding problem in the clinical management of 
breast cancer is overtreatment. It is estimated that 
approxi  mately 55 to 75% of breast cancer patients who 
receive adjuvant chemotherapy would do equally well 
without it [1], but identifying this low-risk population 
with a high enough predictive value (≥90%) is not 
possible using standard prognostic factors such as lymph 
node status or tumour size. Several recently developed 
gene expression classiﬁ   ers have shown promise of 
achieving the required predictive values.
One such classifer is Oncotype DX, a prognostic test 
based on the expression levels of 21 genes, which has 
been shown to identify low-risk patients with an accuracy 
of at least 90%, but is restricted to lymph node-negative 
oestrogen receptor-positive (ER+) breast cancer [2]. 
Another classiﬁ  er is the 7 gene immune response (IR) 
module, which allows identiﬁ  cation of low-risk patients 
in oestrogen receptor-negative (ER-) breast cancer [3]. 
Both of these signatures appear to be robust, demon-
strating a high predictive value across many diﬀ  erent 
breast cancer cohorts [2,3]. Gene Ontology (GO) 
analyses of prognostic signatures [2-6] have shown that 
speciﬁ  c biological processes play particularly important 
roles and that this is subgroup-speciﬁ  c. Th   us, while cell-
proliferation is strongly prognostic in ER+ breast cancer 
[6], the clinical heterogeneity of ER- breast cancers 
appears to be explained mainly by diﬀ  erential expression 
of genes related to immune response pathways, 
highlighting the need to conduct survival analysis within 
speciﬁ  c breast cancer subgroups [7-10].
The article
In line with this, Li and colleagues [11] have recently 
conducted a novel bioinformatic analysis of existing 
breast cancer expression data sets in order to identify 
gene expression modules that may predict patients at low 
risk of distant metastasis in speciﬁ  c breast cancer sub-
groups. A common diﬃ   culty in identifying robust prog-
nostic gene signatures is the presence of noise and 
spurious signals, which often render the resulting gene 
signatures unstable to perturbations. To overcome these 
limitations, Li and colleagues used a novel multiple 
survival screening (MSS) algorithm, designed to extract 
the most robust signals from the data [11]. Using this 
algorithm, Li and colleagues report novel prognostic gene 
modules of high negative predictive values (87 to 100%) 
and that are related to cancer hallmarks, notably cell-
cycle, apoptosis and cell-adhesion [11]. Th  e modules 
were derived using only one data set [12], and while 
individual modules were not prognostic across all eight 
validation sets examined, speciﬁ  c non-linear combi  na-
tions of these modules were. Th   is suggests that classiﬁ  ers 
built from non-linear combinations of modules related to 
distinct cancer hallmarks may yield more powerful 
predictors than those based on individual modules or 
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be speciﬁ  c for either ER+ or ER- breast cancer, further 
supporting the view that cancer subtype analyses are 
necessary [6,7].
Li and colleagues’ work is also signiﬁ  cant for two other 
reasons. First, by dissecting prognostic gene lists into 
various cancer hallmarks they identiﬁ  ed  prognostic 
modules (for example, apoptosis) that are normally only 
associated with the primary tumour and not with the 
subsequent risk of relapse or distant metastasis. A similar 
ﬁ  nding implicating apoptosis as a molecular determinant 
of distant metastasis was made in a diﬀ  erent study [13]. 
Second, genes making up the prognostic modules were 
mapped to a protein interaction network and many were 
shown to directly interact with genes known to be 
mutated in breast cancer (COSMIC) [14]. Interestingly, 
the prognostic power of the modules could be related to 
these driver genes, as other sets of genes with the same 
GO annotations and also direct neighbours of the drivers 
were observed to be as prognostic as the original modules. 
Th   is may explain the redundancy in prognostic gene sets, 
which is often observed in gene expression studies.
The viewpoint
Th   e insights provided by Li and colleagues are important, 
yet there are some cautionary remarks. First, a predictive 
value of 90% is only of clinical relevance if this can be 
achieved using a genuine single-sample classiﬁ  er. 
However, it would appear that the algorithm of Li and 
colleagues [11] is not a single-sample predictor, since the 
speciﬁ  c weights in the centroids are retrained in each of 
the validation sets. Th   us, the validation presented is only 
of the actual gene sets, and not of a single classiﬁ  er. 
Th   erefore, the predictive values quoted should be 
interpreted with caution. In contrast, the Oncotype DX 
and IR module classiﬁ  ers are each deﬁ  ned by a single 
centroid and therefore constitute (modulo a trivial gene-
wise recentering and rescaling) bona-ﬁ  de single-sample 
predictors. In other words, the Oncotype and IR module 
centroids used to classify test samples are unchanged and 
unique to the training set. Th   us, it remains to be seen if a 
single-sample classiﬁ  er derived with the MSS algorithm 
[11] could be applied in a clinical setting.
Another important limitation of this study is the sole 
reliance on one data set [12] to infer prognostic gene sets. It 
is very likely that speciﬁ  c prognostic modules may have 
been missed, specially for the minority ER- subgroup, for 
which one data set would typically not provide the necessary 
sample numbers and power [7]. Th  is may explain why Li 
and colleagues do not ﬁ  nd a prognostic immune response 
module in ER- breast cancer, when in fact many other 
studies have reported such a signature [3,8,9].
Probably, the most important insight from Li and 
colleagues’ work is the observation that non-linear 
combinations of prognostic modules related to diﬀ  erent 
cancer hallmark GO terms may signiﬁ  cantly improve the 
prognostic power of gene expression signatures. Th  is 
makes sense because more often than not gene 
expression signatures are biased towards those genes and 
GO terms with the largest eﬀ  ect sizes, thereby diluting 
the smaller yet equally important predictive eﬀ  ects of 
other genes or GO terms. Alternatively, the interactions 
between cancer hallmarks are likely to be non-linear and 
therefore non-linear combinatorial classiﬁ   ers may be 
required to capture these eﬀ  ects. Th  us, development of 
further algorithmic tools that incorporate such non-
linearities may be a fruitful endeavour.
Th  e observation by Li and colleagues that underlying 
these robust prognostic modules may be a common set of 
mutated driver genes is an important one and supports 
similar observations made by at least two other groups 
[15,16]. We envisage that as the quality and coverage of 
protein interaction networks improves, and as we 
approach the completion of a ﬁ  nal catalogue of mutated 
breast cancer genes, methods that interpret gene expres-
sion, protein expression and protein phosphorylation 
data in the context of these structural signalling networks 
and breast cancer genes are likely to provide us with the 
biological insights needed to drive this ﬁ  eld forward.
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